Exact Sciences strategy in cancer testing, NASDAQ shares in a competitive health sector

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 14:48.

Exact Sciences (US30063P1057) is listed on NASDAQ under the ticker EXAS, giving the cancer diagnostics specialist access to global equity capital. The stock competes in the S&P 500 health technology universe with peers such as Guardant Health and Illumina.

Position in cancer diagnostics

Exact Sciences focuses on molecular diagnostics for colorectal and other cancers, positioning itself within the medical specialties segment of the broader health technology sector. The company’s tests target early detection, aiming to improve outcomes in one of the highest-burden disease areas worldwide.

In the US market, the company faces competition from other liquid biopsy and genomics players, including Guardant Health and Illumina, which are also active in screening and oncology testing. This competitive set shapes expectations for growth, margins and research spending.

Long-term strategic themes

From a long-term perspective, Exact Sciences operates at the intersection of preventive healthcare and data-driven medicine, where payers and regulators closely monitor cost effectiveness. The company relies on reimbursement decisions and guideline inclusion to support the adoption of its tests.

Broader sector commentary from analysts tracking medical specialties on NASDAQ highlights that oncology diagnostics firms often balance expansion in test menus with the need to control selling and marketing costs. For investors, this places emphasis on how companies like Exact Sciences manage scale and profitability over time, rather than on short-term price moves.

How the company earns money

Exact Sciences generates revenue primarily by selling cancer screening and diagnostic tests to physicians, health systems and laboratories, with reimbursement from public and private payers. The flagship portfolio includes stool-based and molecular tests used in colorectal cancer screening, alongside additional oncology assays.

Where the shares trade today

The Exact Sciences shares (US30063P1057) trade on NASDAQ under the ticker EXAS, with the latest verifiable quote and market capitalization reported in US dollars on the exchange’s data pages.

This text is for informational purposes only and does not contain investment advice, personal recommendations or an offer to buy or sell securities.